|
| 38084497 | A wearable device perspective on the standard definitions of disability progression in multiple sclerosis. | Mult Scler | 2024 |
| 37418931 | NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis. | | 2023 |
| 36098960 | Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. | European Journal of Neurology | 2023 |
| 36411081 | Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy. | Neurology: Neuroimmunology and NeuroInflammation | 2023 |
| 37744364 | Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control. | | 2023 |
| 38094990 | Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulness. | | 2023 |
| 37630995 | Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. | | 2023 |
| 38073652 | Comorbidity in the aging population with multiple sclerosis: a Danish nationwide study. | | 2023 |
| 38058171 | An update on combination therapies for multiple sclerosis: where are we now? | | 2023 |
| 37956521 | Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study. | | 2023 |
| 36586351 | Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study. | | 2023 |
| 37337838 | The peripheral endocannabinoid system and its association with biomarkers of inflammation in untreated patients with multiple sclerosis. | | 2023 |
| 37274207 | Scanner agnostic large-scale evaluation of MS lesion delineation tool for clinical MRI. | | 2023 |
| 36773010 | Cluster headache polygenetic risk and known functional variants of CYP3A4 are not associated with treatment response. | | 2023 |
| 36764284 | The uncertainty period preceding the clinical defined SPMS diagnosis and the applicability of objective classifiers - A Danish single center study. | | 2023 |
| 36761410 | Aerobic exercise does not affect serum neurofilament light in patients with mild Alzheimer's disease. | | 2023 |
| 37321014 | Cerebrospinal fluid soluble CD27 is associated with CD8 T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis. | | 2023 |
| 37384281 | Socioeconomic status of the elderly MS population compared to the general population: a nationwide Danish matched cross-sectional study. | | 2023 |
| 37191113 | Cladribine Effects on T and B Cells and T Cell Reactivity in Multiple Sclerosis. | | 2023 |
| 36623393 | Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. | | 2023 |
| 37058764 | Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-up. | | 2023 |
| 36692938 | Plasma neurofilament light significantly decreases following treatment in Lyme neuroborreliosis and is not associated with persistent symptoms. | | 2023 |
| 37369602 | Intrathecal CD8CD20 T Cells in Primary Progressive Multiple Sclerosis. | | 2023 |
| 37307006 | Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. | | 2023 |
| 37364374 | Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience. | | 2023 |
| 36604748 | The gut microbiota in multiple sclerosis varies with disease activity. | | 2023 |
| 37506490 | Citrullination of myelin basic protein induces a Th17-cell response in healthy individuals and enhances the presentation of MBP85-99 in patients with multiple sclerosis. | | 2023 |
| 35178641 | Fatal JC-virus Granular Cerebellar Neuronopathy in a Patient Diagnosed with ALPS and Hypogammaglobulinemia. | J Clin Immunol | 2022 |
| 35653498 | Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7â¿¿T MRI study. | Brain | 2022 |
| 36171103 | Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark. | Journal of Neurology, Neurosurgery and Psychiatry | 2022 |
| 35835563 | Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. | Neurology: Neuroimmunology and NeuroInflammation | 2022 |
| 36030719 | Mapping grip-force related brain activity after a fatiguing motor task in multiple sclerosis. | NeuroImage: Clinical | 2022 |
| 35832609 | Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis. | | 2022 |
| 35637426 | Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. | BMC Medical Research Methodology | 2022 |
| 36279600 | Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study. | Multiple Sclerosis and Related Disorders | 2022 |
| 35688630 | Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis. | Journal of Neurology, Neurosurgery and Psychiatry | 2022 |
| 35672145 | Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. | Neurology: Neuroimmunology and NeuroInflammation | 2022 |
| 36124837 | All anti-CD20 monoclonal antibodies have similar efficacy and risks: No. | Multiple Sclerosis Journal | 2022 |
| 36257152 | Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis. | Multiple Sclerosis and Related Disorders | 2022 |
| 35661562 | Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis. | Multiple Sclerosis and Related Disorders | 2022 |
| 32434821 | Response to: 'Neuroinflammatory events after anti-TNFα therapy' by Kaltsonoudis . | Annals of the Rheumatic Diseases | 2022 |
| 34791952 | Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort. | Multiple Sclerosis Journal | 2022 |
| 34850641 | Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. | Multiple Sclerosis Journal | 2022 |
| 35182499 | The prognostic value of neurofilament light chain in serum. | Lancet Neurology, The | 2022 |
| 34949134 | Extended dosing of monoclonal antibodies in multiple sclerosis. | Multiple Sclerosis Journal | 2022 |
| 35112578 | Peripheral helper T cells in the pathogenesis of multiple sclerosis. | Multiple Sclerosis Journal | 2022 |
| 34644452 | Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study. | European Journal of Neurology | 2022 |
| 34536228 | Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. | CNS Drugs | 2021 |
| 32202196 | Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. | Multiple Sclerosis Journal | 2021 |
| 33591593 | Neutrophil-to-lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review. | Acta Neurologica Scandinavica | 2021 |